TMO Intrinsic Value – Thermo Fisher Scientific Reports Second Quarter Earnings Results for Fiscal Year 2023
August 29, 2023
🌥️Earnings Overview
On June 30, 2023, THERMO FISHER SCIENTIFIC ($NYSE:TMO) announced their financial report for the second quarter of the fiscal year 2023. Their total revenue for the quarter was USD 10.7 billion, representing a 2.6% decrease from the same quarter of the previous year. Additionally, their net income for the same period dropped by 18.1%, amounting to USD 1.4 billion.
Share Price
The stock opened at $555.0 and closed at $574.4, representing a 0.6% increase from its prior closing price of 570.9. This positive performance is indicative of the company’s financial health and resilience. This division is a key driver of the company’s growth as it provides a comprehensive range of analytical instruments, equipment, reagents, consumables, software, and services for the laboratory research market.
Overall, THERMO FISHER SCIENTIFIC continues to demonstrate its commitment to shareholder value through a strong financial performance. The company is well positioned to capitalize on the growth of its core products and services in the future, while expanding into new markets as well. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for TMO. More…
| Total Revenues | Net Income | Net Margin |
| 43.52k | 5.72k | 14.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TMO. More…
| Operations | Investing | Financing |
| 7.69k | -4.66k | -1.81k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TMO. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 94.11k | 50.19k | 113.36 |
Key Ratios Snapshot
Some of the financial key ratios for TMO are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.4% | 15.7% | 16.6% |
| FCF Margin | ROE | ROA |
| 13.5% | 10.5% | 4.8% |
Analysis – TMO Intrinsic Value
GoodWhale has conducted an in-depth analysis of THERMO FISHER SCIENTIFIC’s wellbeing and the fair value of its shares. After taking into account the company’s growth potential, competitive environment, and revenue trends, our proprietary Valuation Line has calculated a fair value for THERMO FISHER SCIENTIFIC stock of around $590.7. However, we have observed that the company’s stock is currently being traded at $574.4, which is a fair price, but slightly undervalued by 2.8%. More…
Peers
In the world of scientific research, Thermo Fisher Scientific Inc is a giant. They are a leading provider of laboratory equipment and services, and their products are used in a wide range of industries. They have a strong presence in the United States, Europe, and Asia, and their competitors are Yourgene Health PLC, Thyrocare Technologies Ltd, Agilent Technologies Inc. All three companies are similar in that they provide scientific research products and services, but each has its own strengths and weaknesses.
– Yourgene Health PLC ($LSE:YGEN)
Yourgene Health PLC is a molecular diagnostics company. The company offers genetic testing services for a range of conditions, including cancer, cardiovascular disease, and inherited disorders. Yourgene Health PLC has a market cap of 29.99M as of 2022 and a Return on Equity of -5.02%. The company’s products and services are used by healthcare professionals, patients, and research institutions worldwide.
– Thyrocare Technologies Ltd ($BSE:539871)
Thyrocare Technologies Ltd. is an Indian in-vitro diagnostics company that offers services in more than 1,200 towns and cities across India. It has a network of over 2,000 collection centres and over 5,000 authorised diagnostic centres. The company was founded in 1996 and has its headquarters in Mumbai, India.
Thyrocare Technologies Ltd. has a market cap of 34.57B as of 2022. The company’s Return on Equity is 21.9%.
Thyrocare Technologies Ltd. is an Indian in-vitro diagnostics company that offers services in more than 1,200 towns and cities across India. It has a network of over 2,000 collection centres and over 5,000 authorised diagnostic centres. The company was founded in 1996 and has its headquarters in Mumbai, India.
– Agilent Technologies Inc ($NYSE:A)
Agilent Technologies is a publicly traded company with a market capitalization of $38.18 billion as of 2022. The company’s return on equity for the same year was 19.27%. Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides products and services that enable customers to make discoveries and accelerate the pace of innovation in their laboratories and businesses. Agilent’s products and services are used in a wide range of applications, including genomics, proteomics, drug discovery, forensics, food safety, and environmental monitoring.
Summary
Investor sentiment towards Thermo Fisher Scientific (TFS) has been slightly dampened by the company’s second quarter financial results. Total revenue for the quarter was USD 10.7 billion, a decrease of 2.6% year-on-year. Net income for Q2 also decreased 18.1% compared to the previous year. Despite this, TFS still has a diversified portfolio of products and services, and its long-term outlook remains strong.
It is expected that the company will improve its performance in the coming quarters, as it continues to focus on cost savings and strategic investments. Investors may want to remain cautiously optimistic in their outlook for TFS.
Related Posts
Recent Posts
